TY - JOUR
T1 - Treatment of multiple myeloma
AU - Rajkumar, S. Vincent
PY - 2011/8
Y1 - 2011/8
N2 - The treatment of multiple myeloma has changed dramatically in the past decade. The increase in the number of active agents has generated numerous possible drug combinations that can be used in the first-line and relapsed settings. As a result, there is considerable confusion about the choice of regimens for initial therapy, role of transplantation in the era of new drugs, end points for therapy, and the role of maintenance therapy. A hotly debated area is whether treatment approaches should achieve cure or disease control, which impacts greatly on the treatment strategy employed. This article provides an update on the treatment of multiple myeloma, with a focus on recent advances, newly diagnosed disease, role of transplantation and maintenance therapy. A synthesized approach to the treatment of myeloma is presented, along with a discussion of key paradigms that need to be challenged.
AB - The treatment of multiple myeloma has changed dramatically in the past decade. The increase in the number of active agents has generated numerous possible drug combinations that can be used in the first-line and relapsed settings. As a result, there is considerable confusion about the choice of regimens for initial therapy, role of transplantation in the era of new drugs, end points for therapy, and the role of maintenance therapy. A hotly debated area is whether treatment approaches should achieve cure or disease control, which impacts greatly on the treatment strategy employed. This article provides an update on the treatment of multiple myeloma, with a focus on recent advances, newly diagnosed disease, role of transplantation and maintenance therapy. A synthesized approach to the treatment of myeloma is presented, along with a discussion of key paradigms that need to be challenged.
UR - http://www.scopus.com/inward/record.url?scp=79961027391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79961027391&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2011.63
DO - 10.1038/nrclinonc.2011.63
M3 - Review article
C2 - 21522124
AN - SCOPUS:79961027391
SN - 1759-4774
VL - 8
SP - 479
EP - 491
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 8
ER -